Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, recently announced it has established a strategic alliance with MPI Research, a leading preclinical research organization with experience in the development of injectable therapeutics.

The strategic alliance creates a preferred partnership relationship that allows Bioject to gain access to a range of capabilities and resources needed for the company to explore its drug-plus-device opportunities, including access to pharmacologic, analytical, safety, and other preclinical testing resources available at MPI Research. The strategic alliance offers MPI Research the opportunity to provide Bioject’s needle-free technology as an alternate delivery option to current drug/biologic manufacturers who may be interested in seeking a more highly competitive and differentiable drug-plus-device brand. This alliance also increases the possibility that Bioject and MPI Research may be able to secure government-sponsored grants or funding directed at improvements in drug-plus-device or vaccine-plus-device-based treatments, which could also lead to potential new drug-plus-device combinations.

“We look forward to our new strategic alliance with MPI Research, which adds the much needed resource capabilities that we have been seeking as a first step in advancing our new drug-plus-device business strategy,” said Ralph Makar, Bioject’s President and CEO. “This is a positive step forward for both organizations and allows each partner to leverage the strengths, resources, and technologies available that we believe will lead to additional new business opportunities for both companies. We are excited and enthusiastic about the potential for the future.”

“Bioject and MPI Research share an innovative and entrepreneurial spirit that creates a synergy vital to our industry,” added CEO and Chairman of MPI Research, Bill Parfet. “It is a pleasure to collaborate with a company that has such highly developed technological expertise and strategic vision.”

Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS provide an empowering technology and works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.